Nanomerics Closes Series A Investment Round With a Strategic Investor and the Silverstein Dream FoundationLONDON, UK / ACCESS Newswire / September 29, 2026 / Nanomerics Ltd, a clinical-stage speciality pharmaceutical company, today announced the closing of its Series A investment round, led by a German strategic investor, with the Silverstein Dream Foundation participating. The investment will allow Nanomerics to further develop its platform technologies, the Molecular Envelope Technology (MET) and METfect, and to advance its ocular pipeline.
Nanomerics CSO Made Honorary Fellow of the Royal Society of ChemistryLONDON, UK / ACCESSWIRE / July 20, 2022 / Nanomerics Ltd., a private speciality pharmaceutical company, today announced that the company's Chief Scientific Officer, Professor Ijeoma F. Uchegbu, had been made an Honorary Fellowship of the UK's Royal Society of Chemistry.
Meet Nanomerics CSO in Montreal This Summer - Nanomerics CSO to Give Plenary Lecture at Controlled Release Society Annual Meeting and Expo in Montreal on 13th July 2022LONDON, UK / ACCESSWIRE / July 11, 2022 / Nanomerics Ltd., a private speciality pharmaceutical company, today announced that Nanomerics' Chief Scientific Officer would be giving a plenary lecture at the Controlled Release Society Annual Meeting and Expo on Wednesday 13th July 2022.
Nanomerics Announces Quotient Sciences as its Clinical Trials PartnerLONDON, UK / ACCESSWIRE / March 28, 2022 / Nanomerics Ltd., a private speciality pharmaceutical company, today announced that the Company had signed an agreement with Quotient Sciences, a drug development and manufacturing accelerator, for the delivery of its Sunlight Trial. The Sunlight Trial will examine the safety and tolerability of OC134 in human volunteers. OC134 is indicated for the treatment of potentially sight threatening cases of
Nanomerics Receives Further Upfront Payment for Anti-Viral Spray AnQlar(TM)LONDON, UK / ACCESSWIRE / March 22, 2022 / Nanomerics Ltd., a private speciality pharmaceutical company, today announced the receipt of a further milestone payment on agreeing the expansion of its anti-viral spray licence (AnQlar™) to Virpax Pharmaceuticals (
NASDAQ:VRPX). Nanomerics recently agreed an expansion of the current North America licence to include world wide rights to the asset. This licence was accompanied by an up-front payment
Better Brain Medicines - Nanomerics Announces Patents Granted in the US, Europe and Japan on the Nose to Brain Use of its Molecular Envelope TechnologyLONDON, UK / ACCESSWIRE / March 14, 2022 / Nanomerics Ltd., a private speciality pharmaceutical company, today announced that the Company had been granted patent protection in multiple jurisdictions for brain delivery applications of its Molecular Envelope Technology (MET). These patents have been granted by the European Patent Office (EP3065779B1), the United States Patent and Trademark Office (US20160279189B1), the Canadian Intellectual
Nanomerics Expands and Moves to New LaboratoriesLONDON, UK / ACCESSWIRE / February 17, 2022 / Nanomerics Ltd., a private speciality pharmaceutical company and University College London spin out, today announced that the Company had invested significantly in its operations, and moved to new laboratories and offices in North London. The laboratories will enable Nanomerics to conduct research within state of the art facilities at the Griffin Institute at Northwick Park and St Mark's Hospital. As
Nanomerics announces patents granted in the US, Europe and Japan and two key publications on the ocular use of its Molecular Envelope TechnologyLONDON, UK / ACCESSWIRE / May 24, 2021 / Nanomerics Ltd., a world leader in molecular engineered delivery technologies, today announced the Company had been granted patent protection in multiple territories for the use of its Molecular Envelope Technology (MET) for ocular applications. These patents have been granted by the European Patent Office (EP3215119 ), the United States Patent and Trademark Office (US10987304) and the Japan
